Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||April 1999|
|Primary Completion Date:||August 2007 (Final data collection date for primary outcome measure)|
PROTOCOL OUTLINE: Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover.
Patients are followed monthly for 6 months, every 2 months for 6 months, every 4 months for a year, and then annually thereafter.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00010413
|United States, Maryland|
|Johns Hopkins University School of Medicine|
|Baltimore, Maryland, United States, 21205|
|Study Chair:||Grant J. Anhalt||Johns Hopkins University|